Faeth Therapeutics, Inc. Common Stock (FTH) Stock Price

FTHStock
$18.80+166.08%52W
Market Cap$485.80M
P/E—
PEG Ratio—
Div yield—
Beta2.31

FTH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)143.00%
Price vs S&P 500 (4W)-42.20%
VGM Score62.98

FTH Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$4.76-$2.84+40.30%(+$1.92)
Q1 2026-$0.62-$131.45-21101.61%(-$130.83)
Q4 2025-$4.81-$3.74+22.25%(+$1.07)
Q3 2025-$4.11-$3.62+11.92%(+$0.49)
Q2 2025-$5.00-$3.91+21.80%(+$1.09)

FTH Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.30
4.36
4.33

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
FTHFaeth Therapeutics, Inc. Common Stock
——B————$18.80
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Faeth Therapeutics, Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.